Acrivon Therapeutics, Inc. — Director's Dealing 2024

Feb 16, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Acrivon Therapeutics, Inc. (ACRV)
CIK: 0001781174
Period of Report: 2024-02-14

Reporting Person: Devroe Eric (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-02-14	Common Stock	F	723	$3.4	Disposed	59710	Direct

Footnotes

F1: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.